Assetmark Inc. Increases Stake in Halozyme Therapeutics

Institutional investor boosts position in biopharmaceutical company by nearly 12%

Apr. 18, 2026 at 7:23am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white close-up image of the inner workings of a complex pharmaceutical manufacturing machine, representing the technical sophistication of Halozyme's drug-delivery technology.Assetmark Inc.'s increased investment in Halozyme Therapeutics highlights the institutional interest in the biopharmaceutical company's innovative drug-delivery platforms.San Diego Today

Assetmark Inc., a financial services firm, increased its stake in Halozyme Therapeutics, Inc. by 11.9% in the fourth quarter, according to a recent SEC filing. The firm now owns 137,415 shares of the biopharmaceutical company's stock, worth approximately $9.25 million.

Why it matters

This investment signals Assetmark's confidence in Halozyme's growth potential and the firm's belief that the stock is undervalued. As a major institutional investor, Assetmark's increased position could influence market sentiment and attract further attention to Halozyme.

The details

Assetmark Inc. acquired an additional 14,568 shares of Halozyme Therapeutics during the fourth quarter, bringing its total position to 137,415 shares. This represents a 11.9% increase in the firm's stake in the biopharmaceutical company. Halozyme Therapeutics is focused on developing and commercializing novel drug-delivery technologies, with its flagship ENHANZE® platform being a key driver of the company's growth.

  • Assetmark Inc. increased its position in Halozyme Therapeutics in the 4th quarter of 2025.

The players

Assetmark Inc.

A financial services firm that manages investments and provides wealth management solutions.

Halozyme Therapeutics, Inc.

A biopharmaceutical company that specializes in the development and commercialization of novel drug-delivery technologies, including its flagship ENHANZE® platform.

Got photos? Submit your photos here. ›

The takeaway

Assetmark's increased stake in Halozyme Therapeutics suggests the firm sees significant upside potential in the biopharmaceutical company's growth prospects. This investment could signal broader market interest in Halozyme's innovative drug-delivery technologies and their potential to improve patient access and convenience.